E-Therapeutics (LON:ETX) has resumed recruitment of patients in its phase 1a trial of its brain cancer drug, ETS2101. after the all-clear from the US regulator.
Recruitment was halted due to a drug storage issue but after the clearance from the US Food and Drug Administration the trial will now continue with higher doses in further cohorts of patients.
Patients who had received treatment with ETS2101 at the time of the temporary halt in recruitment were able to continue to be dosed in accordance with trial protocols.
The trial is being conducted at the University of California San Diego Moores Cancer Centre.
A UK trial is also underway into the use of the ETS2101 (dexanabinol) in a variety of solid tumours.